Sign in Subscribe
Securities law

Securities Class Action Filed Against Replimune Group, Inc.

Strategic Insights

— 1 min read

Investors who suffered losses in Replimune Group, Inc. may have grounds for a securities class action lawsuit. Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune. The firm reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action.

The lawsuit alleges that Replimune and its executives made false and/or misleading statements about the IGNYTE trial, which led to the FDA deeming it inadequate and not well-controlled. As a result, the company's statements about its business, operations, and prospects were materially false and misleading. When the true details entered the market, investors suffered damages. On July 22, 2025, Replimune's stock plummeted over 73% after the company received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for RP1.

Key Takeaways:

  • Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc.
  • The firm reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action.
  • The lawsuit alleges that Replimune and its executives made false and/or misleading statements about the IGNYTE trial.
  • The company's stock plummeted over 73% after receiving a Complete Response Letter from the FDA.
  • Investors who suffered losses exceeding $50,000 may be eligible to participate in a securities class action lawsuit.
  • Faruqi & Faruqi, LLP is a leading national securities law firm with offices in New York, Pennsylvania, California, and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.

Statistics:

  • Replimune's stock plummeted over 73% on July 22, 2025.
  • The deadline to seek the role of lead plaintiff in a federal securities class action is September 22, 2025.
  • Investors who suffered losses exceeding $50,000 may be eligible to participate in a securities class action lawsuit.

Sources:

  • Faruqi & Faruqi, LLP
  • Press release entitled "Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma"
  • The U.S. Food and Drug Administration (FDA)
  • Nasdaq: REPL

Read more